Chapter 3

Self-Micro Emulsifying Drug Delivery Systems (SMEDDS) for Phytopharmaceuticals

Sahaya Merlin S [a*], V.Jayashree [b]

[a*] *Student, B.Pharm IV Year, School of Pharmaceutical Sciences, VISTAS, Chennai 600117, India*

[b] *Associate Professor, Department of Pharmacology, School of Pharmaceutical Sciences, VISTAS, Chennai 600117, India*

* *Corresponding author: jeya.sps@vistas.ac.in*

Abstract

Phyto-pharmaceuticals have gained increasing attention due to their therapeutic potential and natural origin. However, their clinical utility is often compromised by poor aqueous solubility, low permeability, chemical instability in the gastrointestinal tract, and extensive first-pass metabolism, leading to poor oral bioavailability. Self-Micro-emulsifying Drug Delivery Systems (SMEDDS) have emerged as a promising lipid-based delivery approach to overcome these challenges. SMEDDS are isotropic mixtures of oils, surfactants, and co-surfactants that spontaneously form fine oil-in-water micro-emulsions upon mild agitation in gastrointestinal fluids. These systems significantly enhance drug solubilization, protect labile constituents, and improve intestinal absorption and lymphatic transport. This chapter provides a comprehensive overview of the formulation, characterization, and evaluation of SMEDDS, with special emphasis on their application in enhancing the bioavailability of key herbal drugs such as curcumin, silymarin, boswellic acids, and quercetin. Moreover, the chapter explores existing hurdles, regulatory

considerations, and the evolving clinical potential of SMEDDS in the advancement of phyto-pharmaceutical drug delivery.

Keywords: Phytop-harmaceuticals; Lipid-based systems; Nanoemulsion; Bioavailability enhancement; Drug solubilization; Lymphatic transport;

1. Introduction

Herbal medicines have formed the basis of health care throughout human history. Even today, a significant portion of the global population relies on plant-derived remedies for primary health care. Despite their widespread usage and therapeutic potential, herbal drugs often face a significant challenge: poor bioavailability. The extent of bioavailability is primarily determined by the compound's dissolution characteristics, its ability to traverse biological membranes, and its resilience against degradation within the gastrointestinal tract .Many phytochemicals are lipophilic, poorly soluble in water, and susceptible to degradation in acidic environments or by enzymatic activity. Consequently, their therapeutic efficacy is reduced when administered orally.

This presents a compelling case for the development of advanced drug delivery systems aimed at enhancing the pharmacokinetic profile of phyto-pharmaceuticals. Common herbal compounds affected by poor bioavailability include curcumin (from Curcuma longa), resveratrol (from grapes), silymarin (from milk thistle), and boswellic acids (from Boswellia serrata).

2. Importance of Bioavailability

Bioavailability refers to the rate and extent to which the active ingredient or active moiety of a drug is absorbed and becomes available at the site of action. For orally administered drugs, this

ISBN 978-819871346-9

depends on dissolution in gastrointestinal fluids, absorption through intestinal walls, and metabolic stability. Many herbal drugs demonstrate poor aqueous solubility and are substrates for efflux transporters like P-glycoprotein or metabolizing enzymes like CYP3A4, resulting in minimal systemic availability.

Improving bioavailability can significantly enhance therapeutic outcomes, reduce dosing frequency, and minimize side effects. Innovative formulation strategies—including micronization, solid dispersion technologies, nanoemulsion systems, and lipid-based carriers such as Self-Microemulsifying Drug Delivery Systems (SMEDDS)—are actively under investigation to enhance the bioavailability of poorly soluble compounds.

3. Need for Advanced Drug Delivery in Herbal Medicines

The pharmaceutical industry is shifting from conventional dosage forms to advanced delivery systems to improve therapeutic outcomes. For herbal drugs, novel delivery systems are essential not only to enhance bioavailability but also to overcome issues of stability, dosage accuracy, and patient compliance.Among various systems explored, Self-Microemulsifying Drug Delivery Systems (SMEDDS) have emerged as promising carriers due to their ability to solubilize lipophilic drugs and promote lymphatic transport. SMEDDS bypass first-pass metabolism and improve absorption via mucosal membranes, making them suitable for delivering phytoconstituents.

4. Self-Micro emulsifying Drug Delivery System [SMEDDS]

Self-Microemulsifying Drug Delivery Systems (SMEDDS) are isotropic mixtures of oil, surfactant, and co-surfactant that spontaneously form oil-in-water microemulsions upon mild agitation in gastrointestinal fluids. They contain droplet sizes typically below 100 nm, offering a large interfacial surface area that facilitates rapid dissolution and absorption. Unlike classical emulsions, SMEDDS undergo self-emulsification without mechanical agitation and maintain their structural integrity due to inherent thermodynamic stability. The ability to encapsulate poorly water-soluble herbal drugs and enhance permeability makes SMEDDS an attractive choice for phytopharmaceutical formulation development.

5. Components of SMEDDS

The development of a SMEDDS formulation requires meticulous identification and fine-tuning of its fundamental components:

Oil Phase: Serves as a solubilizing agent for lipophilic drugs. Representative lipid-based carriers often include medium-chain triglycerides, unsaturated fatty acids like oleic acid, and ester derivatives such as ethyl oleate.

Surfactants: Aid in reducing interfacial tension and facilitate microemulsion formation. Non-ionic surfactants like Tween 80, Cremophor EL, and Labrasol are commonly used.

Co-surfactants: Help in achieving the desired flexibility of the interfacial film, enabling formation of microemulsion. Transcutol P and PEG 400 are widely favored as auxiliary solubilizers in SMEDDS formulations.

6. SMEDDS Improves Herbal Drug Bioavailability

SMEDDS contribute to improved bioavailability through multiple functional advantages, including: Increased solubilization: Lipophilic phytoconstituents dissolve in the oil phase, maintaining them in a solubilized form. Protection from degradation: The lipidic encapsulation in SMEDDS acts as a physical and chemical barrier,

ISBN 978-819871346-9

mitigating the exposure of phytoconstituents to gastric acidity and enzymatic hydrolysis within the gastrointestinal tract. Enhanced absorption: The nano-sized droplets increase surface area and promote efficient intestinal uptake. Lymphatic transport: Lipid-based systems may bypass hepatic metabolism by entering lymphatic circulation. Rapid onset of action: Swift self-emulsification in gastrointestinal fluids expedites the dissolution and uptake of the drug, thereby enabling an earlier onset of its therapeutic response.

7. Case Studies of Herbal Drugs with SMEDDS

Several herbal bioactives have been successfully formulated into SMEDDS, resulting in significant improvement in pharmacokinetics and therapeutic efficacy: Curcumin; Poorly soluble in water, curcumin shows enhanced anti-inflammatory and anti-cancer activity when formulated in SMEDDS. Boswellic Acids; Used for osteoarthritis and inflammatory bowel disease, their SMEDDS formulations increase oral bioavailability. Silymarin; A Hepatoprotective flavonolignan from milk thistle, silymarin's bioavailability improved markedly with SMEDDS. Quercetin; A dietary flavonoid known for antioxidant and cardioprotective effects, quercetin’s permeability and stability are enhanced through SMEDDS.

8. SMEDDS contribute to improved bioavailability through multiple functional advantages, including

Thermodynamically stable formulation with spontaneous emulsification. Simplified Production and Commercial Scalability: The formulation's adaptability to conventional encapsulation methods—such as soft and hard gelatin capsules—enables efficient scale-up and industrial manufacturing without necessitating complex processing techniques. Dose reduction is possible due to improved bioavailability. Potential for improved patient compliance due to better efficacy and reduced side effects. Improved stability during storage as compared to aqueous formulations.

9. Limitations and Challenges

- Not suitable for hydrophilic drugs or herbal extracts with polar constituents.
- Potential toxicity of surfactants and solvents requires safety assessment.
- Regulatory hurdles in herbal formulation standardization and validation.
- Expensive screening and optimization process including the need for ternary phase diagrams.
- Difficulty in predicting in vivo behavior from in vitro performance due to variability in gastrointestinal physiology.

10. Evaluation of SMEDDS Formulations

Evaluation of SMEDDS includes multiple in vitro and in vivo studies to ensure their stability, efficacy, and reproducibility.

Key evaluation parameters include:

- Droplet size and Polydispersity Index (PDI): Measured using dynamic light scattering (DLS). Ideally, droplet size should be <100 nm for enhanced absorption.
- Zeta potential: Indicates surface charge and predicts physical stability of the formulation.
- Emulsification time: Time taken to emulsify upon dilution; shorter times are preferred.

ISBN 978-819871346-9

- Thermodynamic stability: Evaluated via heating-cooling cycles, centrifugation, and freeze-thaw cycles.
- Drug content and uniformity: Essential to ensure dose accuracy.
- In vitro drug release: Studied using dialysis membrane and simulated intestinal fluid.
- In vivo pharmacokinetic studies: Provide bioavailability data and therapeutic correlation.

11. Optimization Strategies for SMEDDS

Optimization of SMEDDS involves a systematic approach to determine the ideal composition using experimental design methods.

Common approaches include:

- Ternary phase diagrams: Help identify self-emulsifying regions using various oil-surfactant-co-surfactant combinations.
- Response Surface Methodology (RSM): Statistical method for analyzing effects of multiple formulation factors.
- Box-Behnken and Central Composite Design: Used for optimizing multiple variables such as droplet size, emulsification time, and drug loading.
- Design of Experiments (DoE): Ensures robust product development and batch-to-batch consistency.
- Optimization is critical to ensure efficacy, safety, and scalability.
- Regulatory Considerations in Herbal SMEDDS
- Formulating herbal medicines in advanced delivery systems such as SMEDDS brings regulatory challenges. Key considerations include:
- Standardization of herbal extracts: Due to batch variability in phytoconstituents.

- Toxicological evaluation of excipients: Surfactants and co-surfactants must be GRAS-approved.
- Compliance with pharmacopeial standards: Assay, stability, dissolution.
- Clinical trials: Safety and efficacy validation in human subjects.
- Patentability and intellectual property: Innovative SMEDDS formulations can be protected under patent laws.
- Global agencies such as WHO, EMA, and CDSCO are evolving regulatory frameworks to accommodate novel herbal delivery systems.

12. Future Perspectives and Clinical Potential

SMEDDS has significant potential in clinical practice for phytopharmaceutical delivery. Ongoing and future advancements include:

SMEDDS for co-delivery: Combining two or more bioactives with synergistic effects.

Targeted SMEDDS: Ligand-functionalized formulations for tissue-specific delivery.

Pediatric and geriatric formulations: Improved palatability and dose flexibility.

Commercialization: Several SMEDDS-based herbal products are under clinical trials.

Personalized medicine: SMEDDS formulations tailored to individual pharmacogenomics profiles.

13. Conclusion and Future Scope

With the growing interest in herbal medicines globally, SMEDDS can be instrumental in bringing standardized, efficacious, and patient-

ISBN 978-819871346-9

friendly formulations to the market. It addresses a major bottleneck in herbal drug delivery; poor bioavailability and provides a scientifically sound approach to improving therapeutic efficacy. Future research should focus on in vivo-in vitro correlation, clinical validation, and regulatory harmonization to make SMEDDS a mainstream strategy in herbal drug delivery.

References

[1] P. Jaisamut, C. Wiwattanawongsa, S. Sangsen, N. Limsuwan, and P. Wiwattanapatapee, "Self-microemulsifying drug delivery system for enhancing solubility and oral bioavailability of quercetin and resveratrol in rats," *Pharmaceutics*, vol. 15, no. 5, p. 1483, May 2023.

[2] S. Setthacheewakul, R. Mahattanadul, N. Phadoongsombut, A. Pichayakorn, and S. Wiwattanapatapee, "Development and evaluation of self-microemulsifying drug delivery system of curcumin," *Asian J. Pharm. Sci.*, vol. 5, no. 2, pp. 84–91, 2010.

[3] T. Iosio, M. Voinovich, M. Grassi, G. Pinto, and P. Perissutti, "Oral bioavailability of silymarin phytocomplex formulated as self-emulsifying pellets," *Drug Dev. Ind. Pharm.*, vol. 37, no. 1, pp. 95–102, Jan. 2011.

[4] C. Sornsuvit, K. Techadamrongsin, and W. Jittiwat, "Pharmacokinetics of silymarin 140 mg soft capsules containing self-microemulsifying drug delivery system (SMEDDS) in healthy Thai volunteers," *Evid.-Based Complement. Altern. Med.*, vol. 2018, pp. 1–8, Aug. 2018.

[5] M. Rawat and P. Srivastava, "A review of strategies for the development of solid self-microemulsifying drug delivery system (S-SMEDDS)," *J. Pharmacogn. Phytochem.*, vol. 13, no. 3, pp. 326–331, 2024.

[6] H. Liu, X. Liang, and Y. Chen, "Self-microemulsifying drug delivery system for improved oral delivery and pharmacokinetics of ferulic acid: Pharmacodynamics in a mouse model of insomnia," *Int. J. Nanomed.*, vol. 16, pp. 7785–7798, 2021.